Janux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) have received a consensus rating of “Moderate Buy” from the sixteen brokerages that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, twelve have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $62.6667.

JANX has been the subject of a number of research analyst reports. Guggenheim started coverage on Janux Therapeutics in a report on Wednesday, September 3rd. They set a “buy” rating and a $72.00 price target for the company. Wall Street Zen raised Janux Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Wedbush reiterated an “outperform” rating and set a $45.00 target price (down from $76.00) on shares of Janux Therapeutics in a research note on Tuesday, December 2nd. Stifel Nicolaus decreased their target price on Janux Therapeutics from $46.00 to $38.00 and set a “buy” rating on the stock in a report on Tuesday, December 2nd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Janux Therapeutics in a research note on Wednesday, October 8th.

Insider Activity at Janux Therapeutics

In related news, insider Andrew Hollman Meyer sold 3,333 shares of Janux Therapeutics stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $32.98, for a total transaction of $109,922.34. Following the completion of the sale, the insider owned 84,974 shares of the company’s stock, valued at approximately $2,802,442.52. The trade was a 3.77% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Over the last ninety days, insiders have sold 23,331 shares of company stock worth $710,862. Insiders own 8.10% of the company’s stock.

Institutional Investors Weigh In On Janux Therapeutics

Several hedge funds have recently bought and sold shares of JANX. California State Teachers Retirement System grew its position in shares of Janux Therapeutics by 1.1% in the second quarter. California State Teachers Retirement System now owns 37,139 shares of the company’s stock valued at $858,000 after purchasing an additional 404 shares during the last quarter. ProShare Advisors LLC boosted its stake in Janux Therapeutics by 8.1% in the 2nd quarter. ProShare Advisors LLC now owns 10,284 shares of the company’s stock valued at $238,000 after purchasing an additional 771 shares during the period. Ameritas Investment Partners Inc. grew its holdings in Janux Therapeutics by 25.6% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,020 shares of the company’s stock valued at $93,000 after buying an additional 820 shares in the last quarter. Virtus Investment Advisers LLC grew its holdings in Janux Therapeutics by 37.9% in the 2nd quarter. Virtus Investment Advisers LLC now owns 3,679 shares of the company’s stock valued at $85,000 after buying an additional 1,011 shares in the last quarter. Finally, MetLife Investment Management LLC increased its position in Janux Therapeutics by 7.9% during the 1st quarter. MetLife Investment Management LLC now owns 18,663 shares of the company’s stock worth $504,000 after buying an additional 1,365 shares during the period. 75.39% of the stock is currently owned by institutional investors and hedge funds.

Janux Therapeutics Trading Down 0.4%

NASDAQ:JANX opened at $15.30 on Friday. The stock has a market capitalization of $920.30 million, a PE ratio of -9.11 and a beta of 2.82. Janux Therapeutics has a 1-year low of $15.16 and a 1-year high of $63.86. The firm has a fifty day simple moving average of $25.98 and a 200 day simple moving average of $24.87.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $0.21. The firm had revenue of $10.00 million for the quarter, compared to the consensus estimate of $3.07 million. On average, equities analysts predict that Janux Therapeutics will post -1.38 earnings per share for the current fiscal year.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.